Weiss Ratings Reiterates “Sell (D)” Rating for PAVmed (NASDAQ:PAVM)

PAVmed (NASDAQ:PAVM)‘s stock had its “sell (d)” rating restated by Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Several other equities research analysts have also recently commented on PAVM. Zacks Research upgraded shares of PAVmed from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Ascendiant Capital Markets boosted their price target on shares of PAVmed from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.00.

PAVmed Trading Down 4.8%

Shares of PAVmed stock opened at $0.41 on Friday. The company’s 50-day moving average price is $0.45 and its two-hundred day moving average price is $0.57. PAVmed has a 52 week low of $0.30 and a 52 week high of $1.25. The stock has a market cap of $8.96 million, a PE ratio of 0.35 and a beta of 1.07.

Institutional Trading of PAVmed

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC boosted its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,676 shares of the company’s stock after buying an additional 41,990 shares during the period. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.